Skip to content
value.today

NexImmune, Inc.

🇺🇸 Gaithersburg, Maryland, USABiotechnologyFounded 2011

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of NexImmune, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$8 MPrivate placement after listing$2 to $10 million

NexImmune, Inc.: Private sale, Jan 2019

Investors in this round

42 investors had bought by the notice of Feb 22, 2019: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for NexImmune, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alain Cappeluti · Executive Officer
  • Scott Carmer · Executive Officer, Director
  • Alan Roemer · Director
  • Bing Yao · Director
  • Paul D'Angio · Director
  • Robert Spiegel · Director
  • Timothy Bertram · Director
  • Tony Yao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alain Cappeluti, Chief Financial Officer. Newest notice filed Feb 22, 2019. Read the notice at the SEC.

equitySEC
Dec 2017$22 MPrivate placement after listing$10 to $50 million

NexImmune, Inc.: Private sale, Dec 2017

Investors in this round

69 investors had bought by the notice of Feb 1, 2018: 69 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for NexImmune, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $25 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$450,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alain Cappeluti · Executive Officer
  • Scott Carmer · Executive Officer, Director
  • Alan Roemer · Director
  • Bing Yao · Director
  • Paul D'Angio · Director
  • Robert Spiegel · Director
  • Timothy Bertram · Director
  • Tony Yao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Trout Capital LLC (CRD 131489) · New York, New YorkSold in CO, CT, NC, NJ

Signed by Alain Cappeluti, Chief Financial Officer. Newest notice filed Feb 1, 2018. Read the notice at the SEC.

equitySEC
Feb 2015$2 MPrivate placement after listingUnder $2 million

NexImmune, Inc.: Private sale, Feb 2015

Investors in this round

4 investors had bought by the notice of Feb 13, 2015: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for NexImmune, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Offer and sale of Convertible Promissory Notes and Warrants, and the underlying shares of Common Stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alain Cappeluti · Executive Officer, Director
  • Kenneth Carter · Executive Officer, Director
  • James Barrett · Director
  • Janis Naeve · Director
  • Jonathan Schneck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alain Cappeluti, Chief Financial Officer. Newest notice filed Feb 13, 2015. Read the notice at the SEC.

debt, optionsSEC
Jul 2014$3 MPrivate placement after listing$2 to $10 million

NexImmune, Inc.: Private sale, Jul 2014

Investors in this round

3 investors had bought by the notice of Jul 25, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for NexImmune, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Offer and sale of Convertible Promissory Notes and Warrants, and the underlying shares of Common Stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alain Cappeluti · Executive Officer, Director
  • Kenneth Carter · Executive Officer, Director
  • James Barrett · Director
  • Janis Naeve · Director
  • Jonathan Schneck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alain Cappeluti, Chief Financial Officer. Newest notice filed Jul 25, 2014. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NexImmune, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2019).

    SEC Form D · Feb 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in NexImmune, Inc.
InvestorKindAmountRoundRoleSource
Alan S. RoemerPersonnot statednot statedHeld Series A, A2 and A3 preferred stock, director (Form 3, 2021)SEC Form 3
Kristi JonesPersonnot statednot statedHeld Series A preferred stock (Form 3, 2021)SEC Form 3
Paul D'AngioPersonnot statednot statedHeld Series A, A2 and A3 preferred stock, director (Form 3, 2021)SEC Form 3
Scott CarmerPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3
Sol J. BarerPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3
Timothy BertramPersonnot statednot statedHeld Series A, A2 and A3 preferred stock, director (Form 3, 2021)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NexImmune, Inc.
NameRoleNamed in
Alain CappelutiExecutive officerFeb 2019
Scott CarmerExecutive officerFeb 2019
Kenneth CarterExecutive officerFeb 2015
Alan RoemerDirectorFeb 2019
Bing YaoDirectorFeb 2019
Paul D'AngioDirectorFeb 2019
Robert SpiegelDirectorFeb 2019
Scott CarmerDirectorFeb 2019
Timothy BertramDirectorFeb 2019
Tony YaoDirectorFeb 2019
Alain CappelutiDirectorFeb 2015
James BarrettDirectorFeb 2015
Janis NaeveDirectorFeb 2015
Jonathan SchneckDirectorFeb 2015
Kenneth CarterDirectorFeb 2015